Spun out of founder Prof. Satpal Virdee’s lab at the world-renowned MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee, Outrun Therapeutics is a biotech company focused on developing small molecule inhibitors of E3 Ligases to stabilize proteins to treat cancer.
The team specialise in developing small molecule inhibitors that prevent protein degradation by targeting E3 ligases. Their lead program focuses on a small molecule inhibitor for a hard-to-treat solid tumour, aiming to stabilize a crucial tumour suppressor protein.
With an emerging pipeline of E3 ligase inhibitors across oncology and other disease indications, Outrun Therapeutics has deep knowledge of the E3 ligase field and wide-ranging experience in cutting-edge drug discovery technologies to facilitate small molecule discovery and development. The R&D team comprises world-class scientists and is supported internally and externally by experts in multiple scientific and commercial disciplines.
The R&D team at Outrun Therapeutics possesses expertise in:
- Protein production and purification
- Biochemical and cellular biology assay development and execution
- Medicinal chemistry and chemical biology
- Cheminformatics and Computer-Aided Drug Design (CADD)
- Structural biology
- Mass spectrometry
- Preclinical animal models